Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Talmadge King, JR., MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address505 Parnassus Ave, Moffitt
    San Francisco CA 94143
    Phone415-476-0909
    vCardDownload vCard
      Other Positions
      TitleDean of the UCSF School of Medicine

      TitleVice Chancellor – Medical Affairs


      Collapse Biography 
      Collapse Education and Training
      University of Colorado Medical CenteFellowshipPulmonary/Critical Care1979
      Emory UniversityResidencyInternal Medicine1977
      Harvard UniversityM.D.School of Medicine1974
      Collapse Awards and Honors
      Foundation of the American Thoracic Society 2012Breathing for Life Award
      Gustavus Adolphus College2012Sesquicentennial Award
      American Academy of Arts and Sciences2011 Fellow
      American College of Physicians 2010Master
      Gustavus Alumni Association, Gustavus Adolphus College2008Alumni Citation
      American Thoracic Society2007Trudeau Medal
      Institute of Medicine, National Academy of Sciences2004Member
      Public Advisory Roundtable of the American Thoracic Society2003PAR Excellence Award
      Association of American Physicians1998Member
      California Thoracic Society1998Elected honorary member
      Colorado Thoracic Society, American Lung Association of Colorado1998Member. Colorado Pulmonary Hall of Fame
      The Fleischner Society 1997Member
      Western Association of Physicians 1993Member
      American Lung Association of Colorado1992James J. Waring Award For Outstanding Leadership in the Treatment of Lung Disease
      American College of Physicians 1986Fellow
      American College of Chest Physicians1984Fellow
      Alumni Association, Gustavus Adolphus College1980First Decade Award for Early Achievement
      Gustavus Adolphus College1970Guild of St. Ansger Honor Society

      Collapse Overview 
      Collapse Overview
      Dr. Talmadge E. King, Jr. is chair of the Department of Medicine at the University of California, San Francisco where he oversees a department of more than 550 full-time faculty, over 500 volunteer clinical faculty, 180 residents, 238 fellows and over 1000 support staff. His focus in patient care is interstitial lung diseases, in particular idiopathic pulmonary fibrosis, sarcoidosis, connective tissue disease, hypersensitivity pneumonitis, drug-induced lung fibrosis and other rare diffuse lung disorders. King's research interests include pathogenesis, diagnosis and management of inflammatory and immunologic lung disease. He has co-authored eight books including the acclaimed reference book, "Interstitial Lung Disease," now in its fourth edition.

      King earned a medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver. He is a member of the American Academy of Arts and Sciences, Institute of Medicine, National Academy of Sciences, Association of American Physicians, American Clinical and Climatological Association and Fleischner Society and is a master of the American College of Physicians and fellow he American College of Chest Physicians. He holds the Julius R. Krevans Distinguished Professorship in Internal Medicine and won the 2007 Trudeau Medal, the highest honor of the American Lung Association and American Thoracic Society.

      Research Interests

      His overall focus has been on understanding the pathogenesis, diagnosis and management of inflammatory and immunology lung injury. Another aim is to develop and evaluate methods that can serially identify the presence and extent of disease activity in these patients.

      Collapse Interests
      Connective Tissue Disease-Associated ILD, Idiopathic Pulmonary Fibrosis, Hypersensitivity Pneumonitis, Sarcoidosis

      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse NIH Awarded Grants
      Collapse Featured Videos

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015 Jul; 109(7):914-22.
        View in: PubMed
      2. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015 May; 3(5):388-96.
        View in: PubMed
      3. Moodley Y, Corte T, Richeldi L, King TE. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Respirology. 2015 Apr; 20(3):389-94.
        View in: PubMed
      4. Costabel U, Albera C, Bradford WZ, Hormel P, King TE, Noble PW, Sahn SA, Valeyre D, Du Bois RM. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(3):198-205.
        View in: PubMed
      5. King TE, Noble PW, Bradford WZ. Treatments for idiopathic pulmonary fibrosis. N Engl J Med. 2014 Aug 21; 371(8):783-4.
        View in: PubMed
      6. Flaherty KR, Fell C, Aubry MC, Brown K, Colby T, Costabel U, Franks TJ, Gross BH, Hansell DM, Kazerooni E, Kim DS, King TE, Kitachi M, Lynch D, Myers J, Nagai S, Nicholson AG, Poletti V, Raghu G, Selman M, Toews G, Travis W, Wells AU, Vassallo R, Martinez FJ. Smoking-related idiopathic interstitial pneumonia. Eur Respir J. 2014 Sep; 44(3):594-602.
        View in: PubMed
      7. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014 Nov; 273(2):570-9.
        View in: PubMed
      8. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE, Leff JA, Noble PW, Sahn SA, du Bois RM. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014 Jul; 19(5):740-7.
        View in: PubMed
      9. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2093-101.
        View in: PubMed
      10. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
        View in: PubMed
      11. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014 Apr; 145(4):723-8.
        View in: PubMed
      12. King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014 Apr 1; 189(7):825-31.
        View in: PubMed
      13. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2014 Jan 15; 189(2):214-22.
        View in: PubMed
      14. Assayag D, Lee JS, King TE. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014; 74(2):158-65.
        View in: PubMed
      15. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014 May; 19(4):493-500.
        View in: PubMed
      16. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jan; 108(1):181-8.
        View in: PubMed
      17. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014 May; 43(5):1421-9.
        View in: PubMed
      18. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014 Feb; 270(2):583-8.
        View in: PubMed
      19. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15; 188(6):733-48.
        View in: PubMed
      20. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen ML, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013 Aug; 144(2):586-92.
        View in: PubMed
      21. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013; 14:73.
        View in: PubMed
      22. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 Jul; 144(1):234-40.
        View in: PubMed
      23. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013 Jul; 1(5):369-76.
        View in: PubMed
      24. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013 Jun; 143(6):1699-708.
        View in: PubMed
      25. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 1; 187(11):1272.
        View in: PubMed
      26. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE, Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013 Sep; 42(3):750-7.
        View in: PubMed
      27. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013 Feb; 107(2):249-55.
        View in: PubMed
      28. Selman M, Pardo A, King TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012 Aug 15; 186(4):314-24.
        View in: PubMed
      29. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24; 366(21):1968-77.
        View in: PubMed
      30. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15; 156(10):684-91.
        View in: PubMed
      31. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Jul 1; 186(1):88-95.
        View in: PubMed
      32. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012 May 15; 185(10):1044-8.
        View in: PubMed
      33. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012 May; 67(5):407-11.
        View in: PubMed
      34. King TE, Collard HR, Richeldi L. Interstitial lung diseases. Preface. Clin Chest Med. 2012 Mar; 33(1):xiii.
        View in: PubMed
      35. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1382-9.
        View in: PubMed
      36. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Aug 15; 184(4):459-66.
        View in: PubMed
      37. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011 Dec 3; 378(9807):1949-61.
        View in: PubMed
      38. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Dec 15; 184(12):1390-4.
        View in: PubMed
      39. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21; 377(9779):1760-9.
        View in: PubMed
      40. King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Jul 1; 184(1):92-9.
        View in: PubMed
      41. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15; 183(6):788-824.
        View in: PubMed
      42. King TE. Smoking and subclinical interstitial lung disease. N Engl J Med. 2011 Mar 10; 364(10):968-70.
        View in: PubMed
      43. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011 May 1; 183(9):1231-7.
        View in: PubMed
      44. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15; 183(4):431-40.
        View in: PubMed
      45. Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, King TE, Horne FM, Nayfield SG, Reynolds HY, Schmader KE, Toews GB, High KP. Workshop on idiopathic pulmonary fibrosis in older adults. Chest. 2010 Sep; 138(3):693-703.
        View in: PubMed
      46. Arjomandi M, Seward J, Gotway MB, Nishimura S, Fulton GP, Thundiyil J, King TE, Harber P, Balmes JR. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility. J Occup Environ Med. 2010 Jun; 52(6):647-52.
        View in: PubMed
      47. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE, Matthay MA, Kim DS. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010 Jul; 299(1):L3-7.
        View in: PubMed
      48. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung. 2010 Apr; 188(2):143-9.
        View in: PubMed
      49. Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010 Apr; 123(4):304-11.
        View in: PubMed
      50. Levinson W, King TE, Goldman L, Goroll AH, Kessler B. Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med. 2010 Mar 11; 362(10):948-52.
        View in: PubMed
      51. Swigris JJ, Wamboldt FS, Behr J, du Bois RM, King TE, Raghu G, Brown KK. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010 Feb; 65(2):173-7.
        View in: PubMed
      52. Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009 Nov; 136(5):1397-405.
        View in: PubMed
      53. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010 Feb; 104(2):296-304.
        View in: PubMed
      54. Buckley JD, Addrizzo-Harris DJ, Clay AS, Curtis JR, Kotloff RM, Lorin SM, Murin S, Sessler CN, Rogers PL, Rosen MJ, Spevetz A, King TE, Malhotra A, Parsons PE. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. Am J Respir Crit Care Med. 2009 Aug 15; 180(4):290-5.
        View in: PubMed
      55. King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009 Jul 18; 374(9685):222-8.
        View in: PubMed
      56. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009 Jun; 135(6):1557-63.
        View in: PubMed
      57. King TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2008 Nov; 9(11):1171-9.
        View in: PubMed
      58. Kinder BW, King TE. Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease. Am J Respir Crit Care Med. 2008 Jun 1; 177(11):1292-3; author reply 1293.
        View in: PubMed
      59. Travis WD, Hunninghake G, King TE, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Müller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med. 2008 Jun 15; 177(12):1338-47.
        View in: PubMed
      60. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. 2008 Jan; 133(1):226-32.
        View in: PubMed
      61. du Bois R, King TE. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax. 2007 Nov; 62(11):1008-12.
        View in: PubMed
      62. King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Jan 1; 177(1):75-81.
        View in: PubMed
      63. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE, Golden JA. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008 Jan; 102(1):150-5.
        View in: PubMed
      64. Kinder BW, Freemer MM, King TE, Lum RF, Nititham J, Taylor K, Edberg JC, Bridges SL, Criswell LA. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus. Arthritis Rheum. 2007 Aug; 56(8):2679-86.
        View in: PubMed
      65. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007 Oct 1; 176(7):636-43.
        View in: PubMed
      66. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007 Oct 1; 176(7):691-7.
        View in: PubMed
      67. Gotway MB, Freemer MM, King TE. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax. 2007 Jun; 62(6):546-53.
        View in: PubMed
      68. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, Gaxiola M, Pérez-Padilla R, Navarro C, Richards T, Dauber J, King TE, Pardo A, Kaminski N. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007; 2(5):e482.
        View in: PubMed
      69. Collard HR, Loyd JE, King TE, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007 Sep; 101(9):2011-6.
        View in: PubMed
      70. Portnoy J, Veraldi KL, Schwarz MI, Cool CD, Curran-Everett D, Cherniack RM, King TE, Brown KK. Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest. 2007 Mar; 131(3):664-71.
        View in: PubMed
      71. Calfee CS, Shah SJ, Wolters PJ, Saint S, King TE. Clinical problem-solving. Anchors away. N Engl J Med. 2007 Feb 1; 356(5):504-9.
        View in: PubMed
      72. Flaherty KR, Andrei AC, King TE, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, Gay SE, Gross BH, Kazerooni EA, Knapp R, Louvar E, Lynch D, Nicholson AG, Quick J, Thannickal VJ, Travis WD, Vyskocil J, Wadenstorer FA, Wilt J, Toews GB, Murray S, Martinez FJ. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007 May 15; 175(10):1054-60.
        View in: PubMed
      73. Kinder BW, Collard HR, King TE. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest. 2006 Jul; 130(1):302-3.
        View in: PubMed
      74. Walter N, Collard HR, King TE. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006 Jun; 3(4):330-8.
        View in: PubMed
      75. Kim DS, Collard HR, King TE. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006 Jun; 3(4):285-92.
        View in: PubMed
      76. Perez RL, Kimani AP, King TE, Aguayo SM, Roman J. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration. 2007; 74(3):297-303.
        View in: PubMed
      77. Wesson DE, King TE, Todd RF, Torres EA, Hellmann DB, Flack JM, Dubose TD, Schuster VL. Achieving diversity in academic internal medicine: recommendations for leaders. Am J Med. 2006 Jan; 119(1):76-81.
        View in: PubMed
      78. Shah NR, Noble P, Jackson RM, King TE, Nathan SD, Padilla M, Raghu G, Rhodes MB, Schwarz M, Tino G, Dubois RW. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct; 22(3):167-74.
        View in: PubMed
      79. Girod CE, King TE. COPD: a dust-induced disease? Chest. 2005 Oct; 128(4):3055-64.
        View in: PubMed
      80. Lynch DA, Travis WD, Müller NL, Galvin JR, Hansell DM, Grenier PA, King TE. Idiopathic interstitial pneumonias: CT features. Radiology. 2005 Jul; 236(1):10-21.
        View in: PubMed
      81. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):963-7.
        View in: PubMed
      82. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE, Bradford WZ, Schwartz DA, Richard Webb W. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15; 172(4):488-93.
        View in: PubMed
      83. King TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005 Aug 1; 172(3):268-79.
        View in: PubMed
      84. King TE, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):171-7.
        View in: PubMed
      85. King TE, Wheeler MB. Inequality in health care: unjust, inhumane, and unattended! Ann Intern Med. 2004 Nov 16; 141(10):815-7.
        View in: PubMed
      86. Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004 Oct 15; 170(8):904-10.
        View in: PubMed
      87. Collard HR, Ryu JH, Douglas WW, Schwarz MI, Curran-Everett D, King TE, Brown KK. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest. 2004 Jun; 125(6):2169-74.
        View in: PubMed
      88. Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med. 2004 May 15; 116(10):662-8.
        View in: PubMed
      89. King TE, Dickinson TA, DuBose TD, Flack JM, Hellmann DB, Pamies RJ, Todd RF, Torres EA, Wesson DE. The case for diversity in academic internal medicine. Am J Med. 2004 Feb 15; 116(4):284-9.
        View in: PubMed
      90. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004 Jan 8; 350(2):125-33.
        View in: PubMed
      91. King TE. Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management. Trans Am Clin Climatol Assoc. 2004; 115:43-76; discussion 76-8.
        View in: PubMed PMC2263760
      92. Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Müller N, Schwartz DA, King TE, Lynch JP, Hegele R, Waldron J, Colby TV, Hogg JC. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003 Oct; 124(4):1215-23.
        View in: PubMed
      93. King TE. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Semin Respir Crit Care Med. 2003 Oct; 24(5):567-76.
        View in: PubMed
      94. Morris DG, Jasmer RM, Huang L, Gotway MB, Nishimura S, King TE. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest. 2003 Sep; 124(3):929-35.
        View in: PubMed
      95. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003 Sep 1; 168(5):538-42.
        View in: PubMed
      96. Collard HR, King TE. Demystifying idiopathic interstitial pneumonia. Arch Intern Med. 2003 Jan 13; 163(1):17-29.
        View in: PubMed
      97. Inoue Y, King TE, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002 Sep 1; 166(5):765-73.
        View in: PubMed
      98. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE, Leinwand LA, Liotta L, Martin GR, Schwartz DA, Schultz GS, Wagner CR, Musson RA. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med. 2002 Jul 15; 166(2):236-46.
        View in: PubMed
      99. King TE. Nonspecific interstitial pneumonia and systemic sclerosis. Am J Respir Crit Care Med. 2002 Jun 15; 165(12):1578-9.
        View in: PubMed
      100. King TE. Racial disparities in clinical trials. N Engl J Med. 2002 May 2; 346(18):1400-2.
        View in: PubMed
      101. Vourlekis JS, Schwarz MI, Cool CD, Tuder RM, King TE, Brown KK. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis. Am J Med. 2002 Apr 15; 112(6):490-3.
        View in: PubMed
      Talmadge's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP